Matthew Dodson1, Donna D Zhang1,2. 1. Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA, 85721. 2. Arizona Cancer Center, University of Arizona, Tucson, AZ, USA, 85724.
Abstract
PURPOSE OF REVIEW: The goal of this review is to summarize the current knowledge in the field regarding the non-canonical activation of the NRF2 pathway. Specifically, we address what role p62 plays in mediating this pathway, which pathologies have been linked to the p62-dependent activation of NRF2, as well as what therapeutic strategies could be used to treat diseases associated with the non-canonical pathway. RECENT FINDINGS: It has recently been shown that autophagic dysfunction leads to the aggregation or autophagosomal accumulation of p62, which sequesters KEAP1, resulting in prolonged activation of NRF2. The ability of p62 to outcompete NRF2 for KEAP1 binding depends on its abundance, or post-translational modifications to its key domains. Furthermore, the relevance of the p62-dependent activation of NRF2 in disease has been demonstrated in human hepatocellular carcinomas, as well as neurodegenerative diseases. SUMMARY: These findings indicate that targeting p62, or the enzymes that modify it, could prove to be an advantageous strategy for treating diseases associated with autophagy dysregulation and prolonged activation of NRF2. Other therapeutic possibilities include restoring proper autophagic function, or directly inhibiting NRF2 or its targets, to restore redox and metabolic homeostasis. Future studies will help further clarify the mechanisms, regulation, and relevance of the non-canonical pathway in driving disease pathogenesis.
PURPOSE OF REVIEW: The goal of this review is to summarize the current knowledge in the field regarding the non-canonical activation of the NRF2 pathway. Specifically, we address what role p62 plays in mediating this pathway, which pathologies have been linked to the p62-dependent activation of NRF2, as well as what therapeutic strategies could be used to treat diseases associated with the non-canonical pathway. RECENT FINDINGS: It has recently been shown that autophagic dysfunction leads to the aggregation or autophagosomal accumulation of p62, which sequesters KEAP1, resulting in prolonged activation of NRF2. The ability of p62 to outcompete NRF2 for KEAP1 binding depends on its abundance, or post-translational modifications to its key domains. Furthermore, the relevance of the p62-dependent activation of NRF2 in disease has been demonstrated in humanhepatocellular carcinomas, as well as neurodegenerative diseases. SUMMARY: These findings indicate that targeting p62, or the enzymes that modify it, could prove to be an advantageous strategy for treating diseases associated with autophagy dysregulation and prolonged activation of NRF2. Other therapeutic possibilities include restoring proper autophagic function, or directly inhibiting NRF2 or its targets, to restore redox and metabolic homeostasis. Future studies will help further clarify the mechanisms, regulation, and relevance of the non-canonical pathway in driving disease pathogenesis.
Authors: Ian M Copple; Adam Lister; Akua D Obeng; Neil R Kitteringham; Rosalind E Jenkins; Robert Layfield; Brian J Foster; Christopher E Goldring; B Kevin Park Journal: J Biol Chem Date: 2010-04-08 Impact factor: 5.157
Authors: Manohar Pilli; John Arko-Mensah; Marisa Ponpuak; Esteban Roberts; Sharon Master; Michael A Mandell; Nicolas Dupont; Wojciech Ornatowski; Shanya Jiang; Steven B Bradfute; Jack-Ansgar Bruun; Tom Egil Hansen; Terje Johansen; Vojo Deretic Journal: Immunity Date: 2012-08-24 Impact factor: 31.745
Authors: Tao Wright; Sarah L Rea; Alice Goode; Andrew J Bennett; Thomas Ratajczak; Jed E Long; Mark S Searle; Christopher E Goldring; B Kevin Park; Ian M Copple; Robert Layfield Journal: Bone Date: 2012-10-29 Impact factor: 4.398
Authors: Hongting Zheng; Samantha A Whitman; Wei Wu; Georg T Wondrak; Pak K Wong; Deyu Fang; Donna D Zhang Journal: Diabetes Date: 2011-11 Impact factor: 9.461
Authors: Cody J Schmidlin; Aryatara Shakya; Matthew Dodson; Eli Chapman; Donna D Zhang Journal: Semin Cancer Biol Date: 2021-05-18 Impact factor: 15.707
Authors: Sandra Vomund; Anne Schäfer; Michael J Parnham; Bernhard Brüne; Andreas von Knethen Journal: Int J Mol Sci Date: 2017-12-20 Impact factor: 5.923